"cancer immunotherapy" trang 4 - tải miễn phí từ tailieunhanh
báo cáo hóa học:

báo cáo hóa học:" Review of the 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (now the Society for Immunotherapy of Cancer)"
10    51    0
The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: A retrospective analysis

The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: A retrospective analysis
10    66    0
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
8    78    0
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
15    77    1
Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme

Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme
7    94    1
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial
10    34    1
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial
10    63    1
Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers

Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers
11    59    1
A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells

A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells
18    21    1
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy

Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
14    1    1
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
22    4    1
Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: A systematic review and meta-analysis

Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: A systematic review and meta-analysis
7    4    1
Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker

Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker
20    4    1
ABPEPserver: A web application for documentation and analysis of substitutants

ABPEPserver: A web application for documentation and analysis of substitutants
7    8    1
Pan-immune-inflammation and its dynamics: Predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy

Pan-immune-inflammation and its dynamics: Predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
11    6    1
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
10    1    1
Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer

Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer
18    1    1
GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers

GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers
25    9    1
Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
24    33    1
Management of early‑stage triple‑negative breast cancer: Recommendations of a panel of experts from the Brazilian Society of Mastology

Management of early‑stage triple‑negative breast cancer: Recommendations of a panel of experts from the Brazilian Society of Mastology
12    1    1